Clinical Study
Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
Table 2
Common adverse events during treatment.
| |||||||||||||||||||||||||||
n: number of patients experiencing adverse event. |